About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

South Korea's five largest pharmaceutical firms posted combined H1 sales of KRW 4.4996 tln and operating profit of KRW 410.6 bln, up 8% and 18% YoY, respectively, the Financial Supervisory Service disclosure system showed. The group includes Yuhan Co

2026-08-04

South Korea's five largest pharmaceutical firms posted combined H1 sales of KRW 4.4996 tln and operating profit of KRW 410.6 bln, up 8% and 18% YoY, respectively, the Financial Supervisory Service disclosure system showed. The group includes Yuhan Corp., Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical, GC Green Cross and Daewoong Pharmaceutical. Licensing revenue and overseas operations were key drivers of performance divergence. With the government cutting generic drug prices, market participants expect high-margin Innovative drugs and new drug performance will determine H2 earnings.

Other News
2026-08-04

ChiNext jumped more than 2%, the Shenzhen Component rose 1.2% and the Shanghai Composite gained 0.15%; CRO-related stocks led the advance.

ChiNext jumped more than 2%, the Shenzhen Component rose 1.2% and the Shanghai Composite gained 0.15%; CRO-related stocks led the advance.
2026-08-04

Trillions of Yen to "Save the Yen": A Review of Joint US-Japan Currency Intervention Actions

Trillions of Yen to "Save the Yen": A Review of Joint US-Japan Currency Intervention Actions
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.